Financial Performance & Targets - The company aims for a 12-13% Return on Invested Capital (ROIC) and over $1 billion Free Cash Flow (FCF) by 2028[11] - The company anticipates a 9-10% Trading Profit Compound Annual Growth Rate (CAGR) and 6-7% Organic Revenue CAGR[11] - The company's 12-Point Plan has led to approximately a 300 basis point increase in ROIC, roughly a 14x increase in FCF, and about a 220 basis point increase in Group trading margin[53] Market Position & Strategy (RISE) - The company is well-positioned in attractive markets valued at approximately $50 billion, with a growth rate of 6%[13] - The company's strategy, RISE (Reach more patients, Innovate to enhance the standard of care, Scale through strategic investment, Execute efficiently), aims to elevate the company[57] - The company aims to reach 20 million patients by 2028, an increase of 5 million from the current 15 million[63] Segment Performance & Innovation - In Sports Medicine, the company holds a 25% global market share with a business valued at $1.6 billion in 2024[152] - In Advanced Wound Management, the company holds a 13% global market share in a $13 billion market[14, 255] - The company has launched 78 new products between 2021 and 2025, with over 50% of revenue growth coming from products launched in the last five years[98] Orthopaedics Turnaround - The company is implementing Ortho360 to drive efficiency and profitability in Orthopaedics[83, 383] - The company plans to reduce the number of product families in Orthopaedics to drive greater efficiency[386] - The company is addressing historical overproduction in Orthopaedics, aiming to align supply and demand and improve inventory health[393]

Strategic Rationale - IBM is acquiring Confluent to advance as a software-led hybrid cloud and AI platform company[8] - The acquisition expands IBM's total addressable market (TAM) in the real-time data streaming and event processing market, which is valued at over $100 billion[10, 22] - The deal is expected to be accretive to adjusted EBITDA within the first full year and to free cash flow in year two after closing[11, 28] Confluent Overview - Confluent has approximately 6,500 total customers, with less than 5% having over $1 million in annual recurring revenue (ARR)[14] - Over 40% of Fortune 500 companies have adopted Confluent's technology[14] - Confluent's last twelve months (LTM) revenue exceeds $1 billion[14] Market Drivers - The number of new applications is expected to exceed 1 billion by 2028[21] - 89% of IT leaders consider data streaming platforms critical or important for achieving their data-related goals[21] - Total enterprise AI spending is projected to surpass $800 billion by 2029, more than 3 times the spending in 2024[21] Synergies and Financials - IBM anticipates approximately $500 million in run-rate operational synergies[28] - The transaction has an enterprise value of $11 billion, funded by cash on hand[29] - Confluent's largest shareholders, holding approximately 62% of the voting power, have agreed to vote in favor of the transaction[29, 31]

Z-Rostudirsen Clinical Trial Results - The DELIVER trial of z-rostudirsen in exon 51 DMD met its primary endpoint with a statistically significant increase in dystrophin at 6 months (p<0.0001)[9] - The Registrational Expansion Cohort (REC) replicated a ~7-fold increase in muscle content-adjusted dystrophin from baseline at 6 months with z-rostudirsen 20 mg/kg Q4W (p<0.0001)[32] - Z-Rostudirsen achieved ~10-fold higher level of unadjusted dystrophin relative to the level reported in Phase 3 trial of SoC[37] - The trial showed sustained functional improvement from baseline across multiple clinical endpoints out to 24 months[9] - At 6 months, TTR velocity improved exceeding MCID relative to placebo with nominal p<0.05[42] and 10MWR velocity improved relative to baseline and placebo with nominal p<0.05[45] Safety and Tolerability - Z-rostudirsen has a favorable safety and tolerability profile up to 36 months[59] - 1,062 doses of z-rostudirsen at 20 mg/kg dose level have been administered to date[25] - No participants have persistent related anemia or thrombocytopenia at 20 mg/kg[68] Regulatory and Commercial Strategy - The company plans to submit a BLA for U S Accelerated Approval in Q2 2026[7] - Potential U S launch is anticipated in Q1 2027, assuming FDA grants Priority Review[7] FORCE Platform Validation - The DELIVER trial data validates the potential of the FORCE platform for targeted drug delivery[67]

Wolters Kluwer Investor Teach-In: Artificial Intelligence December 8, 2025 Investor Teach-In: Artificial Intelligence – December 2025 1 Forward-looking statements This presentation contains forward-looking statements. These statements may be identified by words such as "expect", "should", "could", "shall", and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from ...

OPTAGE Inc Summary - OPTAGE's consumer business generated ¥258.3 billion in revenue in FY2024, with 54% from FTTH services, 35% from mobile business, and 11% from business solutions[12] - OPTAGE has 1.7 million FTTH subscribers and 1.37 million mobile subscribers as of end-October 2025[7] - OPTAGE aims to transition to a business portfolio where Business Solutions exceed 50% of revenue by FY2035, targeting approximately ¥430 billion in revenue and ¥75 billion in ordinary profit[68, 69] - OPTAGE plans to invest approximately ¥300 billion in growth areas by 2035 to enhance competitiveness and grow as a core non-energy company[59] Kanden Realty & Development Co,Ltd Summary - Kanden Realty & Development's revenue nearly doubled and profit before taxes increased by 2.8 times from 2016 to 2024[82, 83] - Kanden Realty & Development aims for FY2030 targets of ¥310 billion in revenue, ¥40 billion in profit before taxes, and an ROA of 4.5% or higher[103, 104] - Kanden Realty & Development has established a capital recycling business model, with 50% of on-balance sheet assets allocated to capital recycling as of FY2024[73, 93, 94] - Kanden Realty & Development targets an annual increase of ¥180 billion from FY2026 to FY2030 by strengthening the capital recycling business[99] Nuclear Power Generation Summary - The company supplies approximately 50% of Japan's operating nuclear capacity, with a total of 6,578 MW[113, 114] - The company has invested approximately ¥1.19 trillion in safety measures for all seven plants under the new regulatory standards[115] - The company aims to maximize the utilization of existing reactors and steadily advance the development of next-generation advanced reactors[140]

Transaction Overview - Ageas will acquire 100% ownership of AG Insurance from BNP Paribas Fortis for EUR 1.9 billion[4] - The transaction will be financed via an equity placement of 18.5 million shares at EUR 60 per share, totaling EUR 1.11 billion, along with existing cash and financing facilities[4] - The closing is subject to regulatory approval and is expected in Q2 2026[4] Strategic Rationale - The acquisition offers strategic flexibility and strengthens Ageas' position for potential future inorganic growth opportunities[22, 25] - It allows for further leveraging of AG Insurance's distribution, technical, and operational expertise to deepen group synergies[25] - The deal re-confirms the long-term nature of the bancassurance distribution agreement with BNP Paribas Fortis and deepens collaboration on investments[8, 25, 41] Financial Impact - The transaction is expected to deliver an attractive levered Return on Invested Capital (ROIC) of 15-16%[26, 40] - It is projected to increase HFCF (Holding Free Cash Flow) per share by 7-8% by 2027[26, 33] - The acquisition is expected to provide an immediate uplift of EUR 160-175 million from Belgium and EUR 15 million from the Reinsurance segment starting in 2028[33] Partnership with BNP Paribas - BNP Paribas will maintain a significant stake in Ageas, with a shareholding cap of 25%-1[52] - The partnership is governed by a Relationship Agreement with a 5-year duration and automatic renewal[52] - BNP Paribas supports Ageas' future growth as an independent and autonomous group[52] Elevate27 Targets - The transaction leads to an upgrade of Elevate27 financial targets, including an increase in HFCF and shareholder remuneration[26, 53, 59, 60] - The shareholder remuneration is expected to increase by +10%[60] - HFCF is expected to increase by +13%[59]

Conference Call on Helvetia Baloise Pro Forma Financial Information Matthias Henny, Group CFO Helvetia Baloise 8 December 2025 Overview of contents 2 1) Key messages and preliminary remarks 2) Pro Forma Financial Information 3) Outlook and next milestones 4) Appendix Key messages Merger of equals to form Helvetia Baloise completed on 5 December 2025. Previous communication on benefits of the deal, including on cash and dividend capacity uplift, remain valid. Preparation for operational integration well adva ...

Acquisition Overview - Agreement to acquire a 49% interest in Ohio Utica upstream and midstream assets for $588 million[3, 10] - The acquisition includes approximately 35,000 net acres with over 100 identified gross locations[4, 10] - The asset includes over 140 miles of gathering pipelines and approximately 90 miles of water delivery systems[4, 10] - Expected to close by the end of Q1 2026, with an effective date of July 1, 2025[5, 10] Production and Financial Projections - 2026 net production is estimated at approximately 65 MMcfe per day, with an anticipated growth rate of over 30% CAGR through the end of the decade[4, 10] - Projected cash flow from operations for CY2026 is approximately $100 million net to NOG, with substantial growth projected[10] - Average annual capital spending of approximately $100 million is expected on the asset through the end of the decade[10] Strategic Rationale - The acquisition strategically positions NOG to benefit from global demand growth for gas driven by LNG, AI, and continued growth in power[10, 12] - The integrated midstream system enhances margins, improving combined asset operating costs by over $0.70/mcfe[15] - The midstream cash flows are expected to grow by 140% by the end of the decade[10]

Project Overview - Gonneville is a globally significant palladium-nickel-copper project in Western Australia, poised to become a new critical minerals mine[1,9] - The project is expected to generate approximately A$4.7 billion in pre-tax free cash flow over an initial 23-year open-pit life[9,117] - Chalice Mining is funded to a targeted Final Investment Decision (FID) in H1 CY28[10,24,117] Resource and Reserve - The Gonneville Resource contains 17 million ounces of palladium-platinum-gold (3E), 960kt of nickel, 540kt of copper, and 96kt of cobalt[23] - The Ore Reserve is estimated at 7.1 million ounces of 3E, 400kt of nickel, 260kt of copper, and 43kt of cobalt[23] - The open-pit phase is designed for an initial 23-year life, exploiting approximately 50% of the Resource[21] Financial Metrics - The Pre-Feasibility Study (PFS) outlines a pre-tax Net Present Value (NPV8%) of A$1.4 billion and an Internal Rate of Return (IRR) of 23%[21] - The project boasts a rapid payback period of approximately 2.7 years at base case prices[21] - Average annual production is projected at 220koz of 3E, 7kt of nickel, 8kt of copper, and 0.7kt of cobalt[21,25] - The project is positioned as the lowest-cost PGM producer in the Western world, with All-In Sustaining Costs (AISC) of US$370/oz 3E[21] Project Execution and Upside - The project benefits from a low strip ratio of 1.2x for the open-pit mine plan[21,68] - Approximately 50% of the Resource remains unmined below the PFS pit, offering future growth potential[21,92] - Chalice Mining owns approximately 2,600ha of farmland surrounding the Resource, de-risking the project[64]

Financial Performance & Guidance - Q3 2025 net product sales grew to $64.1 million, a 65% increase compared to Q3 2024[10, 158] - Rigel increased its 2025 net product sales guidance to $225 million - $230 million, up from $210 million - $220 million[12] - Rigel anticipates 2025 total revenue of ~$285 million to $290 million[162] - Cash, cash equivalents & short-term investments as of September 30, 2025, was $137.1 million compared to $77.3 million as of December 31, 2024[162] Product Performance - TAVALISSE Q3 2025 net product sales reached $44.7 million, a 70% increase compared to Q3 2024[16] - GAVRETO Q3 2025 net product sales reached $11.1 million, a 56% increase compared to Q3 2024[16] - REZLIDHIA Q3 2025 net product sales reached $8.3 million, a 50% increase compared to Q3 2024[16] R289 Clinical Development - In a Phase 1b study in R/R lower-risk MDS, 33% (6/18) of evaluable transfusion-dependent patients receiving ≥500 mg QD achieved RBC-TI >8 weeks[124, 131] - The median duration of RBC-TI was 22.9 weeks (9 - 104.3)[124] Strategic Collaborations - Contract revenues from collaborations were $5.4 million in Q3 2025[158]